Erschienen in:
13.07.2023 | ASO Author Reflections
ASO Author Reflections: Characteristics of Surgery for Biliary Tract Cancer that Should be Considered During the Design of Future Clinical Trials
verfasst von:
Shin Kobayashi, MD, PhD, Masafumi Ikeda, MD, PhD, Kohei Nakachi, MD, PhD, Makoto Ueno, MD, PhD, Takuji Okusaka, MD, PhD, Akiko Todaka, MD, PhD, Sohei Satoi, MD, PhD, Akira Tomokuni, MD, PhD, Masaru Konishi, MD, PhD, Junji Furuse, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2023
Einloggen, um Zugang zu erhalten
Excerpt
Several large-scale randomized clinical trials investigating the efficacy of adjuvant chemotherapy (AC) for resected biliary tract cancer (BTC) have recently been reported, among which the Adjuvant S-1 for Cholangiocarcinoma Trial [JCOG1202, (ASCOT)] clearly demonstrated the efficacy and safety of adjuvant S-1 by intention-to-treat analysis.
1 While it is reported that the baseline patient characteristics of study cohorts in clinical trials of anticancer treatments differ from those in routine clinical practice due to the stringent eligibility criteria of the clinical trials, there is a lack of studies evaluating factors relevant to enrollment in clinical trials among patients undergoing surgery for BTC. …
